AU2002313713B2 - Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same - Google Patents

Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same Download PDF

Info

Publication number
AU2002313713B2
AU2002313713B2 AU2002313713A AU2002313713A AU2002313713B2 AU 2002313713 B2 AU2002313713 B2 AU 2002313713B2 AU 2002313713 A AU2002313713 A AU 2002313713A AU 2002313713 A AU2002313713 A AU 2002313713A AU 2002313713 B2 AU2002313713 B2 AU 2002313713B2
Authority
AU
Australia
Prior art keywords
lapachone
pharmaceutical composition
beta
pharmaceutically acceptable
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002313713A
Other languages
English (en)
Other versions
AU2002313713A1 (en
Inventor
Zhiwei Jiang
Dasharatha G. Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of AU2002313713A1 publication Critical patent/AU2002313713A1/en
Application granted granted Critical
Publication of AU2002313713B2 publication Critical patent/AU2002313713B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
AU2002313713A 2001-07-31 2002-07-31 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same Ceased AU2002313713B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30893501P 2001-07-31 2001-07-31
US60/308,935 2001-07-31
US09/975,776 2001-10-10
US09/975,776 US6962944B2 (en) 2001-07-31 2001-10-10 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
PCT/US2002/024262 WO2003011224A2 (en) 2001-07-31 2002-07-31 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same

Publications (2)

Publication Number Publication Date
AU2002313713A1 AU2002313713A1 (en) 2003-05-29
AU2002313713B2 true AU2002313713B2 (en) 2007-03-29

Family

ID=26976533

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002313713A Ceased AU2002313713B2 (en) 2001-07-31 2002-07-31 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same

Country Status (13)

Country Link
US (1) US6962944B2 (cg-RX-API-DMAC10.html)
EP (1) EP1420777A4 (cg-RX-API-DMAC10.html)
JP (1) JP2005507861A (cg-RX-API-DMAC10.html)
KR (1) KR100734341B1 (cg-RX-API-DMAC10.html)
CN (1) CN1561209A (cg-RX-API-DMAC10.html)
AU (1) AU2002313713B2 (cg-RX-API-DMAC10.html)
BR (1) BR0211613A (cg-RX-API-DMAC10.html)
CA (1) CA2455567A1 (cg-RX-API-DMAC10.html)
EA (1) EA007075B1 (cg-RX-API-DMAC10.html)
IL (2) IL160108A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA04000994A (cg-RX-API-DMAC10.html)
NZ (1) NZ531335A (cg-RX-API-DMAC10.html)
WO (1) WO2003011224A2 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
US20040209942A1 (en) * 2002-07-17 2004-10-21 Li Chiang J. Activated checkpoint therapy and methods of use thereof
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
WO2003022248A1 (en) * 2001-09-13 2003-03-20 Korea Institute Of Science And Technology Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
US6890950B2 (en) * 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
US7361691B2 (en) * 2002-12-02 2008-04-22 Arqule, Inc. Method of treating cancers using β-lapachone or analogs or derivatives thereof
WO2005053682A2 (en) * 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
CA2556823A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of lung cancer
WO2005082355A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treatment of colon cancer
CA2555950A1 (en) 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US8614228B2 (en) * 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006020719A2 (en) * 2004-08-11 2006-02-23 Arqule, Inc. Aminoacid conjugates of beta - lapachone for tumor targeting
ITMI20041763A1 (it) * 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
US7771751B2 (en) * 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
TW200824692A (en) * 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
BRPI0810717A2 (pt) 2007-04-30 2016-05-24 Arqule Inc sulfonato hidroxi de composto de quinona e seus usos
CN101801937A (zh) 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
EP3121281B1 (en) * 2007-08-27 2021-03-31 1Globe Health Institute LLC Compositions of asymmetric interfering rna and uses thereof
EP2217580B1 (en) 2007-10-12 2011-12-21 ArQule, Inc. Substituted tetrazole compounds and uses thereof
WO2009051752A1 (en) * 2007-10-16 2009-04-23 Arqule, Inc. Novel lapachone compounds and methods of use thereof
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20090073381A (ko) * 2007-12-31 2009-07-03 주식회사 머젠스 심장질환의 치료 및 예방을 위한 약제 조성물
KR101528265B1 (ko) * 2010-04-16 2015-06-11 코웨이 주식회사 베타-라파콘을 유효성분으로 포함하는 주름개선용 화장료 조성물
US20130261142A1 (en) * 2010-12-15 2013-10-03 Hung-Cheng Lai Compounds used for treating cancer and the use thereof
KR101583755B1 (ko) 2012-10-29 2016-01-19 코웨이 주식회사 베타-라파콘을 유효성분으로 포함하는 신경계 질환 예방 및 치료용 조성물
RU2530886C1 (ru) * 2013-06-24 2014-10-20 Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан" Водорастворимый комплекс включения бета-циклодекстрин-гистохром, обладающий пролонгированным антиоксидантным действием
WO2019143192A1 (ko) * 2018-01-18 2019-07-25 (주)나디안바이오 듀니온을 유효성분으로 포함하는 탈모의 예방 또는 개선용 조성물
CN112076157B (zh) * 2019-06-14 2022-04-26 首都医科大学 拉帕醇纳米脂质体制剂及其制备方法和应用
IL299755A (en) * 2020-07-10 2023-03-01 Nadianbio Ltd A pharmaceutical preparation for the prevention or treatment of cancer that contains a naphthoquinone-based compound and inhibits an immune checkpoint as active ingredients
AU2022286925A1 (en) 2021-05-29 2023-12-21 1Globe Health Institute Llc Short duplex dna as a novel gene silencing technology and use thereof
EP4347829A1 (en) 2021-05-29 2024-04-10 1Globe Health Institute LLC Asymmetric short duplex dna as a novel gene silencing technology and use thereof
MX2024007452A (es) * 2021-12-15 2024-07-09 Sillajen Inc Composiciones farmaceuticas que comprenden beta-ciclodextrinas modificadas.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
WO2000061142A1 (en) * 1999-04-14 2000-10-19 Dana-Farber Cancer Institute, Inc. Method and composition for the treatment of cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827452A (en) 1955-05-31 1958-03-18 Univ Minnesota Stabilization of materials
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
HU184066B (en) 1979-12-28 1984-06-28 Chinoin Gyogyszer Es Vegyeszet Plant growth regulating substance and process for preparing such compound
HU181703B (en) 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
NZ199543A (en) 1981-01-23 1985-04-30 Wellcome Found Inclusion complexes of cyclodextrins and cardiac clycosides;pharmaceutical formulations
JPS57126802A (en) 1981-01-30 1982-08-06 Mitsubishi Petrochem Co Ltd Benzophenone-3,3'-disulfonate-capped compound of beta-cyclodextrin
JPS57200361A (en) 1981-06-03 1982-12-08 Sumitomo Chem Co Ltd "indomethacin(r)" pharmaceutical with low irritant action
US4383992A (en) 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58144376A (ja) 1982-02-23 1983-08-27 Sumitomo Chem Co Ltd ベンゾジアゼピン誘導体−シクロデキストリン包接化合物
HU190818B (en) 1982-11-09 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing complexes of piperonyl-butoxide-cyclodextrin
HU190584B (en) 1983-03-11 1986-09-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara,Rt,Hu Process for the production of heptakis/2,6-di-o-methyl-beta-cyclodextrin
DE3400488A1 (de) 1983-03-16 1984-09-20 Kraftwerk Union AG, 4330 Mülheim Elektrohydraulischer kompaktantrieb fuer ventile von turbomaschinen, insbesondere turbinen
EP0146841A3 (de) 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
EP0147685B1 (de) 1983-12-17 1989-04-26 Hoechst Aktiengesellschaft Ether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
MC1711A1 (fr) 1984-11-26 1986-09-22 Ciba Geigy Ag Compose alkylidene-dioxy
MC1710A1 (fr) * 1984-11-26 1986-09-22 Ciba Geigy Ag Composes azotes de derives oxo
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
WO1994004145A1 (en) 1992-08-21 1994-03-03 Dana Farber Cancer Institute Treatment of human viral infections
WO1996011005A2 (en) 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
AU6901296A (en) * 1995-08-24 1997-03-19 Dana-Farber Cancer Institute Beta-lapachone derivatives as antitumor agents
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
AU6777596A (en) * 1995-08-25 1997-03-19 Dana-Farber Cancer Institute Treatment of human prostate disease with beta-lapachone derivatives
US5883270A (en) 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
EP1261337B1 (en) 2000-02-28 2008-09-10 The University Of British Columbia Topoisomerase inhibitors for treatment of surgical adhesions
US6890950B2 (en) 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
WO2000061142A1 (en) * 1999-04-14 2000-10-19 Dana-Farber Cancer Institute, Inc. Method and composition for the treatment of cancer

Also Published As

Publication number Publication date
US20030091639A1 (en) 2003-05-15
US6962944B2 (en) 2005-11-08
CN1561209A (zh) 2005-01-05
NZ531335A (en) 2007-08-31
JP2005507861A (ja) 2005-03-24
CA2455567A1 (en) 2003-02-13
EP1420777A2 (en) 2004-05-26
IL192937A0 (en) 2009-02-11
BR0211613A (pt) 2004-11-09
KR100734341B1 (ko) 2007-07-03
WO2003011224A2 (en) 2003-02-13
EA007075B1 (ru) 2006-06-30
EA200400242A1 (ru) 2004-12-30
MXPA04000994A (es) 2005-02-17
IL160108A0 (en) 2004-06-20
WO2003011224A3 (en) 2003-05-08
KR20040054667A (ko) 2004-06-25
EP1420777A4 (en) 2009-03-04

Similar Documents

Publication Publication Date Title
CA2455567A1 (en) Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
AU2002313713A1 (en) Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7074824B2 (en) Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US8529917B2 (en) Micelle encapsulation of a combination of therapeutic agents
AU2016202145B2 (en) Methods of Increasing Solubility of Poorly Soluble Compounds and Methods of Making and Using Formulations of Such Compounds
JP4334229B2 (ja) プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
US20110311592A1 (en) Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
Tommasini et al. Combined effect of pH and polysorbates with cyclodextrins on solubilization of naringenin
JP5021305B2 (ja) 水溶性ジテルペンの調製方法およびその適用
Dua et al. Investigation of enhancement of solubility of norfloxacin β-cyclodextrin in presence of acidic solubilizing additives
Tang et al. Liprosomes loading paclitaxel for brain-targeting delivery by intravenous administration: In vitro characterization and in vivo evaluation
CN104069065B (zh) 一种注射用桂皮醛亚微乳剂的制备方法及其应用
AU2016209724B2 (en) Nanocarrier delivery system for hydrophobic substances
WO2023060320A1 (en) Topical protein based formulation
MX2008001981A (es) Composiciones anestesicas acuosas que comprenden propofol.
Luftensteiner et al. Evaluation of mitoxantrone-loaded albumin microspheres following intraperitoneal administration to rats
Richard et al. Delivery of ROS Generating Anthraquinones Using Reduction‐Responsive Peptide‐Based Nanoparticles
Ahad et al. Formulation and Evaluation of Kaempferol‐Loaded Invasomes Gel: In Vitro Characterization, Antioxidant, and Cytotoxicity Assessment
CN112716914A (zh) 白蛋白包裹的卡巴他赛阳离子纳米脂质载体及其制备方法
US20180021257A1 (en) Water-soluble pharmaceutical composition comprising at least one therapeutically active substance and at least one substance capable of forming micelles

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired